The Great Point Partners LLC Takes Position in Foamix Pharmaceuticals Ltd. (FOMX)

The Great Point Partners LLC Takes Position in Foamix Pharmaceuticals Ltd. (FOMX)

Great Point Partners LLC bought a new position in Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) during the third quarter, Holdings Channel reports. The institutional investor bought 2,769,425 shares of the specialty pharmaceutical company’s stock, valued at approximately $25,645,000. Foamix Pharmaceuticals makes up about 6.5% of Great Point Partners LLC’s investment portfolio, making the stock its 5th largest position. Great Point Partners LLC owned about 9.03% of Foamix Pharmaceuticals as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Geduld E E bought a new stake in Foamix Pharmaceuticals during the third quarter valued at $156,000. Alpine Partners VI LLC bought a new stake in Foamix Pharmaceuticals during the second quarter valued at $109,000. LMR Partners LLP bought a new stake in Foamix Pharmaceuticals during the second quarter valued at $112,000. Northern Trust Corp bought a new stake in Foamix Pharmaceuticals during the third quarter valued at $223,000. Finally, Menta Capital LLC increased its stake in Foamix Pharmaceuticals by 29.0% in the second quarter. Menta Capital LLC now owns 145,508 shares of the specialty pharmaceutical company’s stock valued at $924,000 after buying an additional 32,697 shares during the period. 64.93% of the stock is owned by institutional investors and hedge funds.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) opened at 10.27 on Thursday. The stock’s 50 day moving average is $10.53 and its 200-day moving average is $9.04. The firm’s market capitalization is $375.87 million. Foamix Pharmaceuticals Ltd. has a one year low of $5.48 and a one year high of $11.27.

Several equities research analysts have weighed in on the stock. TheStreet downgraded shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 3rd. Zacks Investment Research downgraded shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 11th.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Want to see what other hedge funds are holding FOMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX).

Related posts

Leave a Comment